Australian Primary Hyperoxaluria Therapeutics Market 2023 To Show Startling Growth During Forecast Period 2023-2028

Report Overview

The Australian Primary Hyperoxaluria Therapeutics Market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Primary Hyperoxaluria (PH) is an ultra-orphan disease caused by genetic mutations, which results in the build-up of overproduction and accumulation of oxalate in the body. This results in the deposition of calcium oxalate crystals in the kidneys and urinary tract, resulting in urolithiasis, nephrocalcinosis, and ultimately kidney failure. As a result of systemic oxalosis, multi-organ damage occurs which affects bones, eyes, skin and the heart.

Affected individuals lack functional levels of a specific enzyme that normally prevents the accumulation of oxalate. In the kidneys, excess oxalate binds with calcium to form a hard compound (calcium oxalate) that is the main component of kidney and urinary stones. Common symptoms include the formation of stones throughout the urinary tract (urolithiasis) and kidneys (nephrolithiasis) and progressively increased levels of calcium in the kidneys (nephrocalcinosis).

There are three main types of PH that are inherited in an autosomal recessive pattern: PH1, PH2 and PH3. PH1 is the most severe primary hyperoxaluria and accounts for approximately 80% of cases. Primary hyperoxaluria has an estimated prevalence of 1 to 3 cases per 1 million population and an incidence rate of approximately 120,000 live births per year. It accounts for 1-2% of paediatric end-stage kidney disease but higher values are reported in specific populations with a high rate of consanguinity.

Market Growth Drivers

Increasing prevalence of Primary Hyperoxaluria disease is one of the major market drivers. However, with rising awareness and increased diagnostic facilities, demand for Primary Hyperoxaluria drugs is expected to be triggered over the forecast period. High investment in research & development by leading industry participants is expected to open new growth window for them. With strong research and development initiative, most of the companies are focusing on innovative and cost-effective drug development

Increase in special designation from the regulatory authority is propelling the growth of PH market. Huge financial support to the researchers for developing novel intervention is boosting the market growth. High demand of disease specific novel treatment can also act as a market driver. The competitive scenario of market and strategic collaborations may also boost the market position during the forecast period.

Market Restraints

However, the high cost of treatment for Primary Hyperoxaluria acts as a major restraint for the market growth. Additionally, limited operating revenue opportunities for research and development of targeted therapies by many market players will be considered as a challenging factor for the growth of the PH market.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/140012/

Top Major Players

The Australian Primary Hyperoxaluria Therapeutics market is a highly competitive market and major key players are adopting strategies; organic as well as inorganic market strategies. The prominent key players prevailing in the Australian market are Alnylam Pharmaceuticals, Fresenius Kabi Australia Pty Ltd., Sanofi-Aventis Healthcare Pty Ltd., Teva Pharma Australia Pty Ltd., Baxter Healthcare Pty Ltd., and Cipla Australia Pty Ltd. among others.

The Australian Primary Hyperoxaluria Therapeutics Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Australian Primary Hyperoxaluria Therapeutics market. This report explores all the key factors affecting the growth of the global Australian Primary Hyperoxaluria Therapeutics market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

To Know More About COVID-19 Impact On Australian Primary Hyperoxaluria Therapeutics Market @ https://www.prudentmarkets.com/sample-request/140012/

Market Segmentation

By Diagnosis:

On the basis of diagnosis, the Primary Hyperoxaluria Therapeutics market can be classified into

Blood Tests
Urine Tests
X-ray Examination
CT scanning
MRI Technique
Biopsy
Molecular genetic testing
Others

Investigation for PH includes measuring urine and plasma oxalate levels, ruling out the major causes of high oxalate levels. X-ray examinations can reveal the presence of kidney stones or calcium oxalate deposits in tissue. Computed tomography (CT) scanning, a specialized imaging technique, uses a computer and x-rays to create a film showing cross-sectional images of certain tissue structures such as kidney tissue. MRI can detect the severity of systemic oxalosis by imaging the retina, heart, and bone in greater detail. A biopsy involves the surgical removal and microscopic examination of a piece of affected tissue, can also reveal the abnormal accumulation of oxalate. Molecular genetic testing for mutations in the specific genes known to cause PH confirms the diagnosis of PH.

By Drugs:

Based on the drugs, the Primary Hyperoxaluria Therapeutics market can be classified into

Calcium Oxalate Urinary Inhibitors
Thiazides
Pyridoxine

Oxlumo is synthetic double-stranded siRNA oligonucleotide; indicated for the treatment of primary hyperoxaluria in all age groups, has been anticipated to attain higher market share over the forecast period. Calcium Oxalate Urinary Inhibitors, like magnesium and orthophosphates are most commonly preferred. Additionally, Thiazides used to decrease calcium in the urine and pyridoxine (vitamin B6) is known to reduce the body's production of oxalate, have been advocated to prevent kidney stones.

By Treatment:

Based on the treatment, the Primary Hyperoxaluria Therapeutics market can be classified into

Shock wave lithotripsy
Percutaneous nephrolithotomy
Ureteroscopy
Combined liver-kidney transplantation
Sequential liver-kidney transplant
Isolated kidney transplant
Isolated liver transplant

Treatment for kidney stones may involve shock wave lithotripsy, percutaneous nephrolithotomy, and ureteroscopy. Combined liver-kidney transplantation is an option whether pre-emptive or after development of end-stage kidney damage. Depending on response to other treatments and the disease severity, options may include combined liver-kidney transplant; sequential liver-kidney transplant; an isolated kidney transplant, or an isolated liver transplant. Transplantation requires life-long immune suppression and carries significant mortality risk.

By Distribution Channels:

In terms of distribution channel, the Primary Hyperoxaluria Therapeutics market can be classified into

Hospital pharmacies
Retail pharmacies
Online pharmacies

In terms of value, the hospital pharmacies accounted for the leading market share in 2020, which is attributable to the fact that the majority of the medications for primary hyperoxaluria treatment are dispensed by the prescription and can only be done by trained medical professionals. Hence, the hospital pharmacies segment is anticipated to enhance the market share over the forecast period.

Top Major Players

The Australian Primary Hyperoxaluria Therapeutics market is a highly competitive market and major key players are adopting strategies; organic as well as inorganic market strategies. The prominent key players prevailing in the Australian market are Alnylam Pharmaceuticals, Fresenius Kabi Australia Pty Ltd., Sanofi-Aventis Healthcare Pty Ltd., Teva Pharma Australia Pty Ltd., Baxter Healthcare Pty Ltd., and Cipla Australia Pty Ltd. among others.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/140012/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global Australian Primary Hyperoxaluria Therapeutics Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global Australian Primary Hyperoxaluria Therapeutics Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Australian Primary Hyperoxaluria Therapeutics market
Chapter 2: Exclusive Summary - the basic information of the Australian Primary Hyperoxaluria Therapeutics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Australian Primary Hyperoxaluria Therapeutics
Chapter 4: Presenting the Australian Primary Hyperoxaluria Therapeutics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the Australian Primary Hyperoxaluria Therapeutics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/140012/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the Australian Primary Hyperoxaluria Therapeutics Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.